Aizon Raises $20M Series C Financing

SAN FRANCISCO, CA, Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, has closed $20 million in a Series C funding round. The round was led by NewVale Capital, a growth equity fund that invests in proven, revenue-generating service businesses in pharmaceuticals and biotechnology. This infusion of capital, combined with the continued support of key investment partners, will enable Aizon to significantly scale, accelerate its development pipeline, and better serve its customers. Aizon stands at the forefront of pharmaceutical manufacturing innovation with its advanced, GMP-compliant, predictive analytics platform, distinguished by its unique combination of industrialized AI and contextualized Historian. This powerful synergy and the platforms flexibility enable Aizon to provide unparalleled insights and enhanced decision-making capabilities in Pharma Manufacturing.